Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.
Hosted on MSN20h
Barclays Downgrades Illumina (ILMN)Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback